TNF receptor superfamily member 1A
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The TNFRSF1A gene provides instructions for making a protein called tumour necrosis factor receptor 1 (TNFR1). This protein is found spanning the membrane of cells, with part of the TNFR1 protein outside the cell and part of the protein inside the cell. Outside the cell, the TNFR1 protein attaches (binds) to another protein called tumour necrosis factor (TNF). The interaction of the TNF protein with the TNFR1 protein causes the TNFR1 protein to bind to two other TNFR1 proteins, forming a three-protein complex called a trimer. This trimer formation is necessary for the TNFR1 protein to be functional.
Video picks for GenesVideo library
Normal function
The TNFRSF1A gene provides instructions for making a protein called tumour necrosis factor receptor 1 (TNFR1). This protein is found spanning the membrane of cells, with part of the TNFR1 protein outside the cell and part of the protein inside the cell. Outside the cell, the TNFR1 protein attaches (binds) to another protein called tumour necrosis factor (TNF). The interaction of the TNF protein with the TNFR1 protein causes the TNFR1 protein to bind to two other TNFR1 proteins, forming a three-protein complex called a trimer. This trimer formation is necessary for the TNFR1 protein to be functional.
The binding of the TNF and TNFR1 proteins causes the TNFR1 protein to send signals inside the cell. Signaling from the TNFR1 protein can trigger either inflammation or self-destruction of the cell (apoptosis). Signaling within the cell initiates a pathway that turns on a protein called nuclear factor kappa B, which triggers inflammation and leads to the production of immune system proteins called cytokines. Apoptosis is initiated when the TNFR1 protein, bound to the TNF protein, is brought into the cell and starts a process known as the caspase cascade.
Conditions referring to this gene or chromosome
Other names
p55
p55-R
TNF-R
TNF-R1
TNF-R55
TNFR-I
TNFR1
TNFR55
TNR1A_HUMAN
tumour necrosis factor binding protein 1
tumour necrosis factor receptor superfamily member 1A
tumour necrosis factor receptor superfamily, member 1A
tumour necrosis factor receptor type 1
tumour necrosis factor-alpha receptor
Patient picks for Genes

Medicine
Telmisartan - an angiotensin receptor blocker
The usual dose is one tablet daily. You can take telmisartan before or after meals. Side-effects are usually mild. They include feeling dizzy and stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with telmisartan, so ask your pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Valsartan - an angiotensin receptor blocker
You can take valsartan either before or after a meal. Any side-effects are usually mild. The most common side-effect is dizziness. Some painkillers may interfere with valsartan and increase the risk of side-effects, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Azilsartan - an angiotensin receptor blocker
Take azilsartan once each day. You can take the tablets either before or after a meal. Any side-effects are usually mild. They include feeling dizzy and having diarrhoea. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers can interfere with azilsartan and increase the risk of side-effects, so ask a pharmacist for advice before you buy any medicines 'over the counter'.
by Michael Stewart, MRPharmS

Medicine
Irbesartan - an angiotensin receptor blocker
Take irbesartan once each day. You can take the tablets before or after meals. Side-effects are usually mild. They include feeling dizzy and mild stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with irbesartan, so ask a pharmacist for advice before you buy any medicines.
by Michael Stewart, MRPharmS

Medicine
Eprosartan - an angiotensin receptor blocker
The usual dose is one 600 mg tablet daily. Side-effects are usually mild. They include headache, feeling dizzy and mild stomach upset. Keep your regular appointments with your doctor to have your blood pressure measured. Some painkillers interfere with eprosartan. Ask your pharmacist for advice before you buy any medicines 'over the counter'.
by Michael Stewart, MRPharmS

Medicine
Losartan - an angiotensin receptor blocker
Take losartan once each day. You can take your doses either before or after a meal. Any side-effects are usually mild, and can include feeling dizzy or light-headed. Some painkillers can interfere with losartan and increase the risk of side-effects, so ask a pharmacist for advice before you buy any medicines 'over the counter'. Do not drink grapefruit juice whilst taking losartan. It can interact with the medicine and alter its effect.
by Michael Stewart, MRPharmS
Related patient information and medicines

Patient information leaflet
Hidradenitis suppurativa
Hidradenitis suppurativa is a long-term (chronic) skin condition that leads to painful and repeated lumps of pus (boils or abscesses). Things that might caus... Hidradenitis suppurativa tends to run in families; about one-third of people with hidradenitis suppurative have a family member who is affected. Hormones. TNF stands for tumour necrosis.

Patient information leaflet
Immunosuppression
Mycophenolate mofetil Mycophenolate mofetil. Monoclonal antibodies - of which there are many ending in "mab", such as bevacizumab, rituximab and trastuzumab. Anti-TNF drugs such as etanercept Etanercept , infliximab, adalimumab, certolizumab and golimumab. (TNF stands for anti tumour necrosis factor, and some of the "mab" medicines above act.

Patient information leaflet
Biological medicines for rheumatoid arthritis
Biological medicines mimic substances produced by the human body, such as antibodies. For example, some of these biological medicines block a chemical called tumour necrosis factor alpha (TNF-alpha) which plays an important role in causing inflammation in the joints. Medicines that block TNF include adalimumab, certolizumab pegol, etanercept,.

Patient information leaflet
Axial spondyloarthritis
It is divided into: 1) Ankylosing spondylitis. Biological medi... The main ones used for axial spondyloarthritis are called tumour necrosis factor (TNF) inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab). Other medicines, such as secukinumab, bimekizumab or ixekizumab, may be used if TNF inhibitors have been.

Patient information leaflet
Marfan syndrome
In people with Marfan syndrome, because the skin is weaker t... They are usually found on the shoulders, back and thighs. Marfan syndrome is caused by a change (mutation) in the genetic material on one of your chromosomes (chromosome number 15). The gene that is affected is responsible for making a special protein called fibrillin. The gene is.

Patient information leaflet
Ankylosing spondylitis
Ankylosing spondylitis is an auto-immune disease. In ankylosing spondylitis, a chemical called cytokine tumour necrosis factor alpha (TNF-alpha) is involved in causing inflammation. Certain medicines in a group called TNF-alpha inhibitors block the action o... In the UK the National Institute for Health and Care Excellence (NICE) recommends that.
Further reading and references
- TNF receptor superfamily member 1A; MedlinePlus, National Library of Medicine.
- Kimberley FC, Lobito AA, Siegel RM, Screaton GR. Falling into TRAPS--receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther. 2007;9(4):217. doi: 10.1186/ar2197.
- Masson C, Simon V, Hoppe E, Insalaco P, Cisse I, Audran M. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS): definition, semiology, prognosis, pathogenesis, treatment, and place relative to other periodic joint diseases. Joint Bone Spine. 2004 Jul;71(4):284-90. doi: 10.1016/j.jbspin.2003.10.008.
- Pettersson T, Kantonen J, Matikainen S, Repo H. Setting up TRAPS. Ann Med. 2012 Mar;44(2):109-18. doi: 10.3109/07853890.2010.548399. Epub 2011 Feb 1.
- Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I, Tighe PJ. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum. 2006 Aug;54(8):2674-87. doi: 10.1002/art.21964.
- Stojanov S, McDermott MF. The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med. 2005 Oct 10;7(22):1-18. doi: 10.1017/S1462399405009749.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

